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Abstract
Introduction: Until September 2019, pre-exposure prophylaxis (PrEP) with tenofovir disoproxil/emtricitabine for HIV preven-
tion was not covered by health insurance plans in Germany, and was only available through private prescriptions with self-pay
or through informal non-prescription sources. The objective of this study was to investigate the proportion of informal PrEP
use among PrEP users and to identify factors of public health relevance that might be associated with informal PrEP use.
Methods: We conducted a cross-sectional study recruiting PrEP users independent of their PrEP source. Clients from
anonymous community testing checkpoints, users of three dating apps for men who have sex with men residing in Ger-
many and users of a PrEP community website, were recruited to complete a short anonymous online survey. Participants
were recruited between 24 July and 3 September 2018. The results were analysed using univariable and multivariable
logistic regressions.
Results: We recruited 2005 participants currently using PrEP. The median age was 38 years, and 80.3% of the participants
identified themselves as male (missing: 19.1%). Overall, 71.6% obtained PrEP through medical services with a private prescrip-
tion or a clinical trial, and 17.4% obtained PrEP through informal sources (missing: 11.0%). The most common informal sources
were ordering online from another country (8.8%), travel abroad (3.6%), and friends (2.5%). Factors associated with informal
PrEP use were on demand/intermittent dosing (adjusted OR: 3.5, 95% CI 2.5 to 5.0) and not receiving medical tests during
PrEP use (adjusted OR: 3.2, 95% CI 2.0 to 5.2). In addition, informal PrEP users who did not take PrEP daily had a strongly
increased risk of starting PrEP without prior medical tests (adjusted stratum-specific OR = 31.7, 95% CI 4.6 to 219.5).
Conclusions: Informal PrEP use was associated with a higher risk of not getting tested before and during PrEP use, which
could lead to HIV infections resistant to tenofovir and emtricitabine if people with undiagnosed HIV use PrEP. Health insur-
ance plans that cover PrEP and the accompanying routine tests could ensure adequate medical supervision of PrEP users and
reduce barriers to PrEP use. Our findings strongly support the implementation of PrEP programmes in countries with similar
patterns of informal PrEP use.
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1 | INTRODUCTION
Pre-exposure prophylaxis (PrEP), with tenofovir disoproxil/
emtricitabine, has been proven to be highly effective in pre-
venting HIV infections in men who have sex with men (MSM)
and other risk groups, both in clinical trials and observational
studies [1-3]. However, the appropriate use of PrEP requires
exclusion of conditions contraindicated for PrEP use, including a
pre-existing HIV infection or compromised kidney function, in
addition to regular monitoring of HIV status, kidney function
and testing for other sexually transmitted infections (STIs) [4-
6]. Current guidelines recommend HIV testing every three
months, STI testing every three to six months and kidney func-
tion testing every six to twelve months [4,5]. PrEP should only
be initiated and maintained in HIV-negative people to avoid
improper antiviral therapy and the emergence of resistance
against tenofovir disoproxil/emtricitabine [1,7]. Currently, PrEP
is only approved for daily dosing in the European Union [8],
but other dosing regimens, such as on-demand dosing or inter-
mittent dosing, were investigated in clinical trials and are also
used in practice in some European countries [9-13].
In Germany, about 86,100 people currently live with HIV
[14]. MSM are the most affected group, with approximately
2700 new infections in 2017. PrEP became available in
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Germany in 2016. However, the costs for the medication and
for the recommended tests (e.g. for HIV, STIs, kidney function)
were not covered by health insurance plans before September
2019. The initially high out-of-pocket costs for obtaining pre-
scription PrEP—more than €800 per month (assuming daily
dosing)—brought many users to start obtaining PrEP through
informal sources, such as ordering online from sources outside
of the European Union [10,15,16]. It is unclear whether infor-
mal PrEP users seek the recommended medical supervision
before and during PrEP use, which could increase the risk of
improper antiviral therapy in undetected HIV infections and the
emergence of HIV-strains resistant to tenofovir disoproxil/
emtricitabine. Between October 2017 and September 2019,
generic PrEP was available in Germany for €40–€70 self-pay
per month (assuming daily dosing) with a private prescription
from a physician, which increased the number of PrEP users
[11,17,18]. The recommended tests for HIV, STIs and kidney
function could be provided by a physician or by anonymous
testing sites in some cities but they required self-pay before
September 2019. However, it is unknown how many people
were using informal PrEP during this period and how they
were medically supervised.
To investigate these questions, we conducted the PrApp
study, a cross-sectional survey recruiting current and former
PrEP users in Germany using geolocation dating apps and other
community resources. The objective of this analysis was to
investigate the proportion of prescription and informal PrEP
use in current PrEP users and to identify factors associated
with informal PrEP use to inform Public Health strategies.
2 | METHODS
2.1 | Study design
The PrApp study is a cross-sectional study that was designed
to investigate PrEP use in MSM residing in Germany [19,20].
Clients of anonymous community testing checkpoints, as well
as users of three dating apps for MSM (Grindr, Planetromeo
and Hornet) and a community website (https://prepjetzt.de/)
were recruited using: a) instant messages or banner advertise-
ments, which linked potential participants to an online ques-
tionnaire; b) flyers distributed in checkpoints containing a link
and a QR code; c) peer-to-peer recruitment. App-advertising
was targeted to profiles of users residing in Germany. We
aimed to recruit a diverse group of PrEP users irrespective of
where they obtained PrEP. Participants were eligible for inclu-
sion if they: a) provided consent for participation and b) were
taking PrEP currently or had taken PrEP in the past. Eligible
participants completed a short anonymous online survey. The
questionnaire was available on mobile phones and desktop
computers and was provided using the VOXCO Acuity4Survey
platform. The questionnaire was provided in German, English,
French, Spanish, Arabic and Turkish. After completion of the
survey, participants could choose to enter a lottery drawing
for gift certificates. Data were stored and analysed in accor-
dance with German and European data protection laws.
2.2 | Outcomes and covariates
The main outcome of this study is the proportion of prescrip-
tion PrEP use and informal PrEP use. Prescription PrEP use
was defined as obtaining PrEP medication through medical
services in Germany (e.g. German pharmacies (local or online)
with a prescription or participation in a clinical trial). Informal
PrEP use was defined as any other PrEP source, including
ordering online from another country, traveling and buying
PrEP abroad, friends, using medication for post-exposure pro-
phylaxis as PrEP, dealers, sex parties and other sources
[21,22].
The questionnaire used in this study can be found in the
appendix (Appendix S1). Self-reported gender was analysed as
“male,” “transgender/non-binary” (someone whose gender iden-
tity does not match the gender assigned at birth [23,24]) and
“intersex” (someone whose sex characteristics do not fit the
normative criteria of female or male [25]). Age was grouped
into the following categories: 18 to 29, 30 to 39, 40 to 49
and 50 to 80 years. The country of origin was grouped into a
binary variable “Germany” and “outside Germany.” The type of
PrEP use was binarized into “daily” and “on demand/intermit-
tent” use, where “on demand use” refers to PrEP use only
around sexual activities [13] and “intermittent” refers to daily
PrEP use for shorter periods of time interrupted by periods
without PrEP use. Time since first PrEP use was grouped into
a binary variable of ≤6 months and ≥7 months. Condom use
while taking PrEP was binarized into “always/often” and “in
about half of the time/sometimes/never.” The number of anal
sex partners within the last six months was grouped as zero
to three partners, four to ten partners and >10 partners. The
stratification for the number of pills taken per month was
based on strata published by Molina et al. [13] and simplified
into three categories.
Answers to reasons for taking PrEP were grouped as fol-
lows (multiple answers per person were allowed): (1) “Protec-
tion when condoms are not used” includes anyone with an
affirmative answer to “I don’t want to use condoms and still
want to protect myself”, “My partner doesn’t want to use con-
doms and I still want to protect myself”, “Sex without a con-
dom is expected by my peers and I still want to protect
myself”, “Sometimes condoms aren’t available and I still want
to be protected”, “It’s more convenient since I don’t have to
talk about or negotiate condom use” or free text answers with
similar statements; (2) “Protection in addition to condoms”
includes anyone with a positive answer to “I want to protect
myself against HIV in case the condom breaks” or “I use con-
doms and I want additional protection”; (3) “Problems using
condoms during sex” includes any positive answer to “I cannot
get an erection when I use a condom but I still want to pro-
tect myself” or free text answers with similar statements; (4)
“Serodiscordant partnership” includes anyone with a positive
answer to “My partner is HIV positive and I want to protect
myself”.
2.3 | Statistical analysis
The answers to categorical items in the questionnaire are dis-
played as absolute numbers or proportions. Continuous vari-
ables are shown using medians and interquartile ranges.
Factors associated with informal PrEP use were investi-
gated using univariable and multivariable logistic regressions.
Co-variates included age, annual gross income, country of ori-
gin, type of PrEP use, time since first PrEP use, average num-
ber of pills taken per month, affordability of generic PrEP,
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tests before starting PrEP, tests while taking PrEP, number of
anal sex partners within the last six months, condom use while
taking PrEP and communication of PrEP use on online profile.
Participants with missing data for any variable included in the
final multivariable regression model were excluded from both
uni- and multivariable analyses (full case analysis). Interactions
were analysed using likelihood ratio tests and calculating stra-
tum-specific effect estimates.
As a sensitivity analysis, we performed the analyses exclud-
ing patients that received PrEP through a clinical trial since
their PrEP use and testing behaviour might differ from other
PrEP users. In addition, participants receiving prescription
PrEP through a German online pharmacy might have misclas-
sified themselves to the informal PrEP use category “Internet/
ordered online from another country”. We performed a sensi-
tivity analysis excluding participants from this category to
investigate the robustness of our findings.
2.4 | Ethical approval
The study protocol was approved by the ethics commission of
the Berlin Chamber of Physicians (Ref: Eth-14/18).
3 | RESULTS
Between 24 July and 3 September 2018, we recruited 2005
participants who were using PrEP (Appendix S2). The median
age was 38 years and 80.3% identified themselves as male
(Table 1).
Most participants were recruited through dating apps
(64.5%), followed by friends (30.9%), a community website
(7.1%) and checkpoints (2.0%). The most common reason for
taking PrEP was to have protection when condoms are not
used, followed by wanting protection in addition to condoms,
having problems using condoms and being in a serodiscordant
partnership.
While obtaining PrEP through medical services was most
common, 17.4% obtained PrEP through informal sources
(Table 1). Informal PrEP users were more likely than prescrip-
tion PrEP users to have first used PrEP longer than six
months ago (adjusted OR (aOR) = 2.6, 95% CI 1.8 to 3.7)
(Table 2). In addition, informal PrEP users were more likely to
use PrEP on-demand or intermittently compared to prescrip-
tion PrEP users (aOR = 3.5, 95% CI 2.5 to 5.0).
Informal PrEP users were more likely to use PrEP without
undergoing the recommended medical tests before starting
PrEP (aOR = 3.0, 95% CI 1.4 to 6.6) or during PrEP use
(aOR = 3.2, 95% CI 2.0 to 5.2). Further stratification revealed
that not getting tested before starting PrEP was strongly
associated with informal PrEP users taking on demand or
intermittent PrEP (adjusted stratum-specific OR = 31.7, 95%
CI 4.6 to 219.5) in contrast to informal PrEP users taking
daily PrEP (Table 3).
Not getting tested during PrEP use was associated with
informal PrEP use regardless of participants using daily or on
demand/intermittent PrEP (Table 3). More informal PrEP
users stated that their country of origin was not Germany
and that generic PrEP for €50–€70 per month was not afford-
able for them (Table 2). We found weak evidence that the
answers regarding the affordability of PrEP differed across
strata of daily versus on demand/intermittent PrEP use
(Table 3). In daily PrEP users, we found that informal PrEP
users were much more likely than prescription PrEP users to
state that they perceived generic PrEP to be unaffordable
(adjusted stratum-specific OR = 11.5, 95% CI 5.3 to 25.3). In
non-daily PrEP users, we did not find evidence for the associa-
tion between informal PrEP use and perceiving generic PrEP
to be unaffordable.
Condom use was low, as 72.5% stated that they used con-
doms on half or less of the occasions they had anal inter-
course (Table 2). We did not find a difference in condom use
between prescription and informal PrEP users. Since taking
PrEP, 50.1% of the participants indicated using condoms less




Median (IQR) 38 (31 to 45)
18 to 29, n (%) 330 (16.5)
30 to 39, n (%) 606 (30.2)
40 to 49, n (%) 475 (23.7)
50 to 80, n (%) 213 (10.6)






Recruited through, n (%) (multiple answers allowed)
Dating apps 1293 (64.5)
Community website 142 (7.1)
Anonymous checkpoint 40 (2.0)
Friends 619 (30.9)
Missing 428 (21.3)
Reasons for taking PrEP, n (%) (multiple answers allowed)
Protection when condoms are not used 1567 (78.2)
Protection in addition to condoms 791 (39.5)
Problems using condoms during sex 554 (27.6)
HIV serodiscordant partnership 158 (7.9)
Other reason/missing 12 (0.6)
Sources of PrEP
Medical services with private
prescription or clinical trial
1436 (71.6)
Online order from another country 177 (8.8)






Sex parties 15 (0.7)
Other 1 (0.1)
Missing 220 (11.0)
IQR, interquartile range; PrEP, pre-exposure prophylaxis.
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Univariable analysisa Multivariable analysisb
OR (95% CI) p-value OR (95% CI) p-value
Total 1436 (100) 348 (100)
Time since first PrEP use
≤6 months 686 (47.8) 91 (26.2) 1 1
≥7 months 656 (45.7) 218 (62.6) 2.5 (1.8 to 3.4) < 0.001 2.6 (1.8 to 3.7) < 0.001
Missing 94 (6.6) 39 (11.2) -
Type of PrEP use
Daily 1034 (72.0) 139 (40.0) 1 1
On demand/intermittent 311 (21.7) 168 (48.3) 4.3 (3.2 to 5.8) < 0.001 3.5 (2.5 to 5.0) < 0.001
Missing 91 (6.3) 41 (11.8) -
Tests before starting PrEP (e.g. HIV, STI, kidney function)
Yes 1391 (96.9) 289 (83.1) 1 1
No 27 (1.9) 43 (12.4) 7.3 (3.9 to 13.9) < 0.001 3.0 (1.4 to 6.6) 0.006
Missing 18 (1.3) 16 (4.6) -
Tests while taking PrEP (e.g. HIV, STI, kidney function)
Yes 1274 (88.7) 223 (64.1) 1 1
No 96 (6.7) 96 (27.6) 6.1 (4.2 to 8.9) < 0.001 3.2 (2.0 to 5.2) < 0.001
Missing 66 (4.6) 29 (8.3) -
Country of origin (%)
Germany 913 (63.6) 164 (47.1) 1 1
Outside Germany 269 (18.7) 99 (28.5) 2.0 (1.5 to 2.8) < 0.001 2.3 (1.6 to 3.2) < 0.001
Missing 254 (17.7) 85 (24.4) -
Number of anal sex partners within the last 6 months, n (%)
0 to 3 190 (13.2) 49 (14.1) 1.2 (0.7 to 1.8) 0.509 1.0 (0.6 to 1.7) 0.978
4 to 10 417 (29.0) 90 (25.9) 1 1
>10 711 (49.5) 164 (47.1) 1.1 (0.8 to 1.5) 0.584 1.2 (0.8 to 1.7) 0.466
Missing 118 (8.2) 45 (12.9) -
Condom use while taking PrEP
Always/often 283 (19.7) 55 (15.8) 1 1
In about half of the
times/sometimes/never
1046 (72.8) 248 (71.3) 1.3 (0.9 to 1.9) 0.203 1.4 (0.9 to 2.1) 0.199
Missing 107 (7.5) 45 (12.9) -
Is PrEP for a price of €50 to €70 per month affordable?
Yes 950 (66.2) 183 (52.6) 1 1
Yes, but it is difficult to manage 417 (29.0) 91 (26.2) 1.4 (1.0 to 1.9) 0.057 1.6 (1.0 to 2.4) 0.040
No 49 (3.4) 57 (16.4) 7.2 (4.4 to 12.0) < 0.001 7.1 (3.8 to 13.1) < 0.001
Missing 20 (1.4) 17 (4.9) -
Communication of PrEP on online profile
Yes 655 (45.6) 131 (37.6) 1 1
No, but mentions it while chatting 453 (31.6) 122 (35.1) 1.3 (1.0 to 1.8) 0.082 1.0 (0.7 to 1.4) 0.993
No 217 (15.1) 53 (15.2) 1.2 (0.8 to 1.8) 0.423 0.9 (0.5 to 1.4) 0.588
Missing 111 (7.7) 42 (12.1) -
Age
18 to 29 years 253 (17.6) 77 (22.1) 1.4 (1.0 to 2.1) 0.077 1.0 (0.6 to 1.6) 0.959
30 to 39 years 514 (35.8) 92 (26.4) 1 1
40 to 49 years 377 (26.3) 98 (28.2) 1.2 (0.8 to 1.7) 0.295 1.3 (0.9 to 1.9) 0.206
50 to 80 years 177 (12.3) 35 (10.1) 0.9 (0.5 to 1.4) 0.597 0.8 (0.4 to 1.4) 0.410
Missing 115 (8.0) 46 (13.2)
Annual gross income, n (%)
<€30,000 320 (22.3) 79 (22.7) 1 1
€30,000 to €39,000 217 (15.1) 55 (15.8) 0.8 (0.5 to 1.2) 0.245 1.6 (0.9 to 2.7) 0.095
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often than before, and 21.3% stopped using condoms com-
pletely (Appendix S3).
PrEP use was communicated on the online dating profile of
44.6% of the participants, and an additional 32.2% indicated
mentioning PrEP use in chats (Table 2). The proportion of par-
ticipants taking PrEP less than 26 days per month was higher
in informal PrEP users (Appendix S3). However, after adjusting
for confounding variables, we did not find an association of
this variable with informal PrEP use (adjusted OR = 1.4, 95%
CI 0.8 to 2.6); thus, the variable was excluded from the multi-
variable regression model.
In the final multivariable model, we did not find differences
between prescription PrEP users and informal PrEP users
regarding age, annual gross income, number of anal sex part-
ners within the last six months, condom use or communicating
PrEP use online (Table 2). Sensitivity analyses excluding par-
ticipants receiving PrEP through a clinical trial (Appendix S4)
or excluding participants receiving informal PrEP online
(Appendix S5) yielded similar results.
4 | DISCUSSION
In this study, which investigated PrEP use in a sample of Ger-
man PrEP users recruited between 24 July and 3 September
2018 (i.e. nine to ten months after sharp price reductions for
generic PrEP medication in Germany), we show that 71.6% of
the participants used prescription PrEP and 17.4% used infor-
mal sources (missing: 11.0%). Informal PrEP users were more
likely to use PrEP on-demand or intermittently and more likely
to forgo medical testing during PrEP use. In addition, informal
PrEP users using on-demand or intermittent PrEP had a high
risk of not getting medical tests before initiating PrEP. Individ-
uals that avoid getting the recommended tests before and
during PrEP increase the risk of using PrEP in case of an undi-
agnosed HIV infection, which consequently increases the risk
of developing tenofovir disoproxil/emtricitabine-resistant HIV
infections.
We were able to recruit a large sample of PrEP users to
comprehensively investigate the extent of informal PrEP use
and associated factors. The recruited population is similar to
previously published studies regarding age, a high number of
sexual partners and low condom use [9-12,16,18,26,27]. Sur-
veys from France and Australia reported informal PrEP use
predominantly in younger populations [16,27], which might be
due to recruitment differences. The proportion of prescription
PrEP use was higher in our study (71.6%) compared to a Ger-
man online survey from 2016 (29.2%) and a study in Berlin
from October 2017–April 2018 (44.4%) [11,17]. Another
study found an even higher proportion of prescription PrEP
users in Germany (98%), which might be due to differences in
recruitment and the underlying study population [18]. This
increase in prescription PrEP use might reflect access to the
more affordable generic PrEP option, which became available
in October 2017. These observations are in line with our find-
ings that more informal PrEP users had been using PrEP for
more than 12 months, which likely started before generic
PrEP became available in Germany.
Regarding the type of PrEP use, previous studies in Bel-
gium, the Netherlands and Australia found that between
23.5% and 48% of the participants preferred non-daily PrEP
[12,28-31]. A single-centre study in France found the prefer-
ence for on-demand PrEP to be as high as 75.6% [9]. In our
study, we found the proportion of on-demand/intermittent
PrEP users to be on the lower end of this spectrum (23.9%).
It will be interesting to monitor the development of daily and
on-demand PrEP use in future surveys.
Regarding the reasons for PrEP use, a qualitative study
identified different types of informal PrEP users: people who
want to avoid condom usage and others who use PrEP as
additional protection in case a condom breaks [32]. Our study
corroborated these findings, showing that the majority the
participants used PrEP for protection in case condoms were
not used, but about 40% also indicated that they preferred
protection in addition to condoms.
The appropriate use of PrEP requires medical testing
before and during use to avoid PrEP use in people with
undiagnosed HIV infections and to ensure the timely diagno-
sis of other STIs [4,5]. In Germany, recommended routine
testing during PrEP use is not covered by health insurance
plans, which might prevent some PrEP users from getting
the recommended tests. In addition, people using informal
PrEP might lack financial resources or even the knowledge






Univariable analysisa Multivariable analysisb
OR (95% CI) p-value OR (95% CI) p-value
€40,000 to €49,000 191 (13.3) 35 (10.1) 0.7 (0.4 to 1.1) 0.156 1.3 (0.7 to 2.3) 0.407
€50,000 to €59,000 144 (10.0) 27 (7.8) 0.7 (0.4 to 1.1) 0.142 1.6 (0.8 to 3.2) 0.153
€60,000 to €69,000 109 (7.6) 31 (8.9) 1.2 (0.7 to 2.0) 0.497 2.4 (1.3 to 4.6) 0.008
≥€70,000 265 (18.5) 55 (15.8) 0.8 (0.6 to 1.3) 0.386 1.7 (1.0 to 3.1) 0.072
Missing 190 (13.2) 66 (19.0) -
CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio, PrEP, PRE-exposure prophylaxis; STI, sexually transmitted infection.
aUnivariable logistic regression model including 1089 participants with formal and 230 participants with informal PrEP use, p-values derived from
Wald test; bmultivariable logistic regression model including 1089 participants with formal and 230 participants with informal PrEP use adjusting
for age, annual gross income, time since first PrEP use, type of PrEP use, tests before starting PrEP, tests while taking PrEP, country of origin,
number of anal sex partners within the last six months, condom use while taking PrEP, affordability of PrEP, communication of PrEP use online;
p-values derived from Wald test.
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anonymous testing sites might not offer all the tests. In our
study, the majority of people stated that they obtained medi-
cal tests before and during PrEP use. The testing frequency
in prescription-PrEP users in our study is higher than results
found in two previously published studies using data col-
lected between 2011 and 2017 [33,34], which might be due
to differences in data capture and more recent dissemination
of testing guidelines. However, we did identify that informal
PrEP users were more likely to forgo testing before or dur-
ing PrEP use. Recurrent out-of-pocket costs for these tests,
a lack of information that these tests are needed and/or a
lack of knowledge where to get access to these tests are
among the possible reasons informal PrEP users do not get
tested. We did not collect data on the causal factors
between informal use and insufficient testing behaviour. This
should be investigated in the future.
Informal PrEP users were more likely to state that they
perceived generic PrEP for €50–€70 per month (assuming
daily dosing) to be unaffordable. Since the price of PrEP
through online sources is still lower than that of generic
PrEP, people with less disposable income might stay on infor-
mal PrEP. Stratification by the type of PrEP use showed that
finding generic PrEP unaffordable was strongly associated
with informal PrEP use in daily users. Interestingly, we did
not find this association for on-demand/intermittent users,
indicating that daily PrEP use without health insurance cov-
erage is likely too expensive for some, and the high cost pre-
vents access to all people who could benefit from it. This is
noticeable in light of recent results indicating that in some
populations daily PrEP might allow for more intercourse
events to be protected against HIV [35,36]. In contrast,
about half of the informal PrEP users indicated that generic
PrEP would be affordable to them. In our study, we did not
investigate reasons why they still opted to obtain informal
PrEP. Possible reasons for the continued use of informal
PrEP could include the inconvenience of managing doctors’
appointments and filling prescriptions, difficulties with finding
a physician willing to prescribe PrEP and/or the stigma asso-
ciated with PrEP.
Since September 2019, PrEP, as well as the accompanying
tests, are covered by statutory health insurances covering
about 90% of the German population, with the remainder
being covered by private health insurances or self-pay. In light
of our results, we strongly support this initiative to ensure
that all people with HIV prevention needs can access PrEP
under medical supervision, regardless of their financial back-
ground and to encourage other countries with similar patterns
of informal use to consider similar measures.
The strength of this study is that we were able to recruit a
large sample of current PrEP users, as small sample sizes
were a common limitation of previous studies [11,17]. In addi-
tion, we were able to recruit participants independent of their
PrEP source using an easily accessible, anonymous online sur-
vey. Since informal PrEP use implies obtaining PrEP medica-
tion from “unauthorised” sources, participants may not have
been as open to report on their experiences in a face-to-face
setting.
Some limitations of this study need to be considered. Since
most of the participants were recruited online, it is unclear
how generalizable the results are for PrEP users not using
online platforms. Also, since we did not have any information
on people who were not willing to participate in the study, we
were not able to investigate potential selection bias. More-
over, some people who informally use antiretroviral medica-
tion to prevent HIV infections might not refer to the
medication as PrEP, and therefore did not participate in this
survey. Thus, we do not know if the results of this study apply
to this group.
Additionally, since the study results relied on self-reported
information by the participants, they might be subject to sev-
eral information biases. People might be likely to provide more
socially acceptable answers on sensitive topics, such as sexual





Likelihood ratio test for interaction
OR (95% CI) p-value OR (95% CI) p-value p-value
Tests before starting PrEP (e.g. HIV, STI, kidney function)
Yes 1 1 0.013
No 0.6 (0.1 to 3.3) 0.567 31.7 (4.6 to 219.5) <0.001
Tests while taking PrEP (e.g. HIV, STI, kidney function)
Yes 1 1 0.833
No 3.5 (1.6 to 7.8) 0.002 3.2 (1.3 to 7.8) 0.009
Is PrEP for a price of €50 to €70 per month affordable?
Yes 1 1 0.058
Yes, but it is difficult to manage 2.0 (1.2 to 3.4) 0.008 2.5 (1.4 to 4.6) 0.003
No 11.5 (5.3 to 25.3) <0.001 1.6 (0.6 to 4.4) 0.407
Multivariable logistic regression model adjusting for age, annual gross income, country of origin, type of PrEP use, time since first PrEP use,
affordability of generic PrEP, tests before starting PrEP, tests during PREP use, number of anal sex partners within the last six months, condom
use, communication of PrEP use online; p-values: Wald test. CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio; PrEP,
pre-exposure prophylaxis; STI, sexually transmitted infection.
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behaviour and condom use. However, our data show that we
were able to recruit people that indicated risky sexual beha-
viour; so, we did not expect this to have a major effect on our
results. In addition, the provided answers might be subject to
recall bias. Since we did not expect either effect to be depen-
dent on the source of PrEP, this effect would be non-differen-
tial between the groups and bias our effect estimates towards
the null value. Participants might not want to disclose their
true source of PrEP since it might be illegal. In this case, some
people with informal sources would be misclassified as using
prescription PrEP. This would make the groups more alike and
bias our effect estimates towards the null value. Considering
these factors, our effect estimates for factors associated with
informal PrEP use might be underestimates. In addition, par-
ticipants receiving prescription PrEP from online pharmacies
might have misclassified themselves into the informal PrEP
category “online order from another country.” This would also
make the categories more alike and bias our effect estimates
towards the null value. However, a sensitivity analysis exclud-
ing participants ordering PrEP online yielded similar results;
thus, we do not believe our findings were substantially
impacted by this factor.
5 | CONCLUSIONS
Our study shows that informal PrEP use is associated with a
higher risk of not getting tested before and during PrEP use,
which can lead to HIV infections resistant to tenofovir diso-
proxil/emtricitabine if PrEP is used in people with undiagnosed
HIV. A substantial proportion of PrEP users, especially infor-
mal PrEP users, struggle with the out-of-pocket costs for
PrEP, potentially impairing access to this prevention tool. Our
data strongly support that PrEP and the corresponding medi-
cal tests should be covered by health insurance plans to
ensure proper use regardless of the financial background of
PrEP users.
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